Clinical Collaboration Zedsen has publicly announced a first clinical research study in partnership with Imperial College Healthcare NHS Trust to validate its non-invasive sensor technology, signaling a potential entry point for hospital-based pilots, research collaborations, and early adopter opportunities in oncology and general health monitoring.

Strong Funding With a Series B of $12M and a valuation around $110M, Zedsen demonstrates solid backing and growth potential, which can support expanded clinical trials, regulatory milestones, and larger-scale deployments in healthcare systems seeking innovative diagnostic and monitoring solutions.

Regulatory Readiness The company emphasizes ISO 13485 quality management and existing tech stack aligned with medical device standards, indicating readiness for regulatory clearance processes and faster time-to-market for hospital procurement and device integration.

Executive Momentum Key leadership appointments since 2021, including a chairman with strategic guidance and a Chief Technology Officer with strong expertise, suggest a focused path to scale product development, strategic partnerships, and enterprise-level sales conversations with health systems.

Healthcare Partnerships Past collaborations with institutions like Worcester College and ongoing ties to research ecosystem players position Zedsen to leverage academic and high-profile hospital partnerships for pilots, case studies, and evidence-based value propositions targeting oncology care and preventive health.